# Neuralink — Healthcare Investment Intelligence

> other · Series C+. MedFuel Intel profile as of 2026-06-12.

Neuralink is developing implantable brain-computer interfaces (BCIs) and has received FDA approval for human trials in May 2023, with the first human implant completed in January 2024. The company, founded by Elon Musk in 2016, has advanced to conducting clinical trials for patients with spinal cord injuries or ALS as of March 2026.

## Key facts (as of 2026-06-12)
- Sector: other
- Stage: Series C+
- Website: https://neuralink.com

## MedFuel assessment
- Intelligence score: 0/100
- Analyses: 0
- Sentiment trend: stable

---
Source: MedFuel Intel — https://medfuelintel.com/company/neuralink-11. Figures reflect MedFuel's analysis; verify against primary sources (SEC, FDA, ClinicalTrials.gov) before any investment decision.